Ziprasidone for Clozapine- or Olanzapine-Associated Diabetes Mellitus
Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
This study is a six-week, open label trial of the novel antipsychotic agent, ziprasidone,
added to a stable dose of clozapine or olanzapine in 40 diabetes mellitus patients, patients
with an impaired fasting glucose or insulin resistance with schizophrenia or schizoaffective
disorder. The first two weeks will be a fixed-dose of ziprasidone 40 mg twice a day. During
weeks 2-6, the ziprasidone dose may be increased up to 80 mg twice a day.